Navigation Links
HeartWare Appoints Timothy J. Barberich to Board of Directors
Date:4/30/2008

Founder, Former CEO of Sepracor Inc. (Nasdaq: SEPR)

FRAMINGHAM, Mass. and SYDNEY, Australia, April 30 /PRNewswire-FirstCall/ -- HeartWare Limited (ASX: HTW) today announced that veteran healthcare executive Timothy J. Barberich has been appointed to its Board as a non- executive director, effective immediately.

Barberich, 60, is the founder and former president, chief executive officer and chairman of Marlborough, MA-based Sepracor Inc., a publicly traded pharmaceutical company with 2007 revenues of US$1.2 billion that specializes in developing drugs for respiratory and central nervous system disorders. Barberich founded Sepracor in 1984 and was president and chief executive officer through 1999 when he also became chairman. He retired in May 2007 but remains Sepracor's chairman.

Barberich also serves on the boards of BioSphere Medical, Gemin X Biotechnologies, Resolyx Pharmaceuticals and serves on the Board of Trustees of Boston Medical Center.

"Tim is an extraordinarily experienced healthcare executive. His record of creating, leading and growing private and publicly traded companies in both the pharmaceutical and medical device arena is remarkable," said HeartWare Chairman Mr. Rob Thomas. "Tim's extensive operational, financial and corporate experience will be of great value to HeartWare as we advance our unique HeartWare(R) LVAD System towards an international market launch and the start of our US clinical trial later this year."

Prior to founding Sepracor, Barberich spent 10 years as a senior executive at Bedford, MA-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets.

Barberich is a graduate of Kings College. He holds a BS degree in Chemistry.

With the addition of Mr. Barberich, the HeartWare Board of Directors now totals 7 members.

About HeartWare

HeartWare develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), designed to treat patients suffering from advanced heart failure. The Company is developing the industry's smallest and least invasive pumps, which it believes will be the key to unlocking the potential of a large and underserved market. The HeartWare(R) LVAD is a full-output pump designed to be implanted in the chest, avoiding the abdominal surgery generally required to implant competing devices. The device is currently the subject of an international clinical trial involving five investigational centres in Europe and Australia. A clinical trial in the U.S. is expected to begin in the first half of 2008.

For further information:

http://www.heartware.com.au US Investor Relations

Howard Leibman Matt Clawson

Director Corporate Development Partner

HeartWare Limited Allen & Caron, Inc.

Email. howard.leibman@heartware.com.au Email. matt@allencaron.com

Tel. +61 2 9238 2064 Tel. +1 949 474 4300


'/>"/>
SOURCE HeartWare Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/13/2017)... -- Research and Markets has announced the addition of the ... ... at a CAGR of 16.83% during the period 2017-2021. ... global biopolymers market for 2017-2021. To calculate the market size, the report ... The report also includes a a discussion of the key vendors operating ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ... process that evaluates the patent estate of a company, its impact and significance, and ... firm leading the way in technologies that transform energy sources such as low dose ...
(Date:1/12/2017)... , Jan. 12, 2017   Protein ... and maker of Flublok Influenza Vaccine ®, ... vaccine candidate had good safety results and induced ... preclinical studies. The product is expected to advance ... months.  In addition, the Institute of Technology in ...
Breaking Biology Technology:
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the ... their offering. The report forecasts the global military biometrics ... The report has been prepared based on an in-depth ... landscape and its growth prospects over the coming years. The report also ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):